Metastasis and carcinoma case studies
Metastasis and carcinoma case studies is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 24k research works in it since 1950. 6.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the metastatic behavior, clinicopathological characteristics, molecular profiling, and therapeutic targets of metastatic carcinomas, particularly from lung tumors and breast cancer. It explores the role of GATA3 as a prognostic marker, the use of immunohistochemistry in diagnosis, and the identification of potential therapeutic targets for these aggressive metastatic cancers.
- Metastatic Carcinomas
- Lung Tumors
- Breast Cancer
- GATA3
- Sarcomatoid Carcinoma
- Pleomorphic Carcinoma
- Immunohistochemistry
- Molecular Profiling
- Therapeutic Targets
- Prognostic Markers
- Research works
- 24k fractional, since 1950
- In the world top 10%
- 1.7k per year above
- Top-10% rate
- 6.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +13% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Metastasis and carcinoma case studies research?
By volume, China and the United States publish the most (827 and 644 works in 2022–2025).
By volume, 2022–2025
- 1 China 827 works
- 2 United States 644 works
- 3 Japan 551 works
- 4 India 180 works
- 5 South Korea 118 works
- 6 Germany 116 works
- 7 Italy 104 works
- 8 Türkiye 91 works
- 9 United Kingdom 87 works
- 10 Russia 81 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Metastasis and carcinoma case studies research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Metastasis and carcinoma case studies research, followed by The University of Texas MD Anderson Cancer Center and Sichuan University.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 24 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 22 works
- 3 Sichuan UniversityChina 16 works
- 4 Cleveland ClinicUnited States 15 works
- 5 Sun Yat-sen UniversityChina 14 works
- 6 Nanjing Medical UniversityChina 13 works
- 7 Chinese PLA General HospitalChina 13 works
- 8 Fujian Medical UniversityChina 11 works
- 9 Memorial Sloan Kettering Cancer CenterUnited States 11 works
- 10 National Cancer Center Hospital EastJapan 11 works
Who are the leading researchers in Metastasis and carcinoma case studies?
The most-cited researchers publishing on Metastasis and carcinoma case studies include Matthew Meyerson and Ralph H. Hruban.
- 1 Matthew Meyerson United States 4.2k citations
- 2 Ralph H. Hruban United States 2.9k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Metastasis and carcinoma case studies research done?
The largest centres of Metastasis and carcinoma case studies research in 2022–2025 are Tokyo (Japan), Beijing (China), Shanghai (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Osaka.
Largest cities, 2022–2025
Where it is the local speciality
- OsakaJP · 51.5 works9.0×
Location quotient: how much more of its research is in Metastasis and carcinoma case studies than the world average.
Where is the best place to study Metastasis and carcinoma case studies?
Among universities, judged by research, Chinese Academy of Medical Sciences & Peking Union Medical College, Fujian Medical University and Keio University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 61.1 | 7.3% | 7.3× | 24 | +108.6% |
| 2 | Fujian Medical UniversityChina | 60.3 | 11.9% | 9.3× | 11 | +125.6% |
| 3 | Keio UniversityJapan | 46.7 | 8.5% | 8.8× | 11 | +16.4% |
| 4 | Sichuan UniversityChina | 40.7 | 7.9% | 2.6× | 16 | +137.9% |
| 5 | Sun Yat-sen UniversityChina | 39.4 | 10.2% | 2.5× | 14 | +57.3% |
| 6 | Nanjing Medical UniversityChina | 38.6 | 4.3% | 7.5× | 13 | +51.7% |
| 7 | Peking UniversityChina | 31.1 | 7.7% | 1.7× | 9 | +114.7% |
| 8 | Sağlık Bilimleri ÜniversitesiTürkiye | 29.1 | 1.4% | 5.0× | 10 | — |
| 9 | All India Institute of Medical SciencesIndia | 24.7 | 4.8% | 4.5× | 10 | +72.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Metastasis and carcinoma case studies research growing?
Output in 2018–2022 was 13% higher than in 2013–2017, peaking in 2019. The fastest-growing topics are Metastasis and carcinoma case studies.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.